Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : SYNSORB (T.SYB)(SYBBF) CURE FOR CANCER? -- Ignore unavailable to you. Want to Upgrade?

To: John Trudeau who wrote (30)	3/24/1999 9:45:00 PM
From: Tupulak	Read Replies (2) \| Respond to of 164

CALGARY, Alberta--(BUSINESS WIRE)--March 23, 1999--SYNSORB Biotech Inc. (''SYNSORB'') (TSE:SYB - news; NASDAQ:SYBB - news) today announced that effective tomorrow before market opens, it has changed its Nasdaq ticker symbol to SYBB from SYBBF. ''SYNSORB has always been and continues to be committed to accommodating our shareholders,'' said Dr. David Cox, President and CEO of SYNSORB. ''This simplified ticker symbol further facilitates that goal.'' SYNSORB began trading on the Nasdaq National Market on February 25, 1998. SYNSORB Biotech Inc. is dedicated to accelerated drug development from the acquisition of promising compounds emerging from basic research through clinical development, and ultimately to providing channels to market for new discoveries. Headquartered in Canada, SYNSORB currently has two products in late stage clinical trials, SYNSORB Pk® for the treatment of verotoxigenic E. coli (VTEC) infections (including O157:H7), and SYNSORB Cd® designed to treat recurrent antibiotic-associated diarrhea (CDAD). SYNSORB has additional compounds in pre-clinical development, including potential cancer treatments and novel antibiotics, with inflammation and anti-virals targeted in the Company's research and development program. This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. These factors include results of current or pending clinical trials, actions by the FDA/HPB and those factors detailed in the Company's registration statement on Form 20 F filed with the Securities and Exchange Commission. Contact: SYNSORB Biotech Inc. Mr. Doug Ball, 403/283-5900 403/283-5907 (FAX) synsorb.com or The Equicom Group Jason Hogan, 416/815-0700 ex 222 416/815-0080 (FAX) United States: 800-385-5451 or SYNSORB Biotech Inc. Mr. Doug Froom, 403/283-5900 403/283-5907 (FAX)

To: John Trudeau who wrote (30)	3/24/1999 10:59:00 PM
From: Techno	Read Replies (1) \| Respond to of 164

I do not disagree with your 2 year time frame but I do feel that there is room for alot of short term upward potential in this stock with even a little promotion. Correct me if I'm totally ignorant but if they plan to raise a substaintial amount of cash to fund operations for two to three years there has to be some promotion kicking in the next couple weeks. Maybe I'm overly optimistic. I can not ignore 800,000 shares in block trades over the past two and a half months in the $3.50 range. As you say the markets and time will tell.